Waddell & Reed Financial’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Waddell & Reed Financial’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-207,685	Closed	-$6.13M	–	636
2016 Q1	$6.13M	Hold	207,685	–	–	0.01%	459
2015 Q4	$9.41M	Hold	207,685	–	–	0.02%	420
2015 Q3	$8.67M	Hold	207,685	–	–	0.01%	430
2015 Q2	$12.5M	Hold	207,685	–	–	0.02%	403
2015 Q1	$16.1M	Buy	+207,685	New	+$12M	0.02%	375

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Waddell & Reed Financial's ONCE Position: Q2 2016 in Review

Waddell & Reed Financial sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2016, closing a stake of 207,685 shares — an estimated $6.13M sold.

Waddell & Reed Financial first reported a position in ONCE in Q1 2015 and held it in 5 quarters. The position peaked at $16.1M in Q1 2015. 115 funds tracked by Wall St. Rank hold ONCE as of Q2 2016.

Waddell & Reed Financial reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
Waddell & Reed Financial sold 207,685 Spark Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $6.13M.
Waddell & Reed Financial first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 5 quarters.
Waddell & Reed Financial's Spark Therapeutics, Inc. Common Stock position peaked at $16.1M in Q1 2015.
115 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Waddell & Reed Financial's 13F filing for Q2 2016, filed 12 Aug 2016.